Reviewer to the NCI SBIR for Novel Imaging Agents, the Innovative Medicines Initiative (IMI), the Swedish foundation for Strategic Research, the Society of Nuclear Medicine for Oncology – Basic Science track and serving as a peered journal's reviewer on topics of molecular imaging, radiopharmaceuticals and apoptosis/angiogenesis imaging
- Consulting for drug and imaging agents from Discovery and Development to Commercialization
- Successfully completed all requirements for the I-Corps @ NIH Program (June-August 2016)
What We Do
We provide consulting in the areas of pharmacy, radiochemistry and radiopharmacy of imaging agents, including Chemistry, Manufacturing and Controls, Pharmacology and Toxicology sections of IND’s, ANDA’s and DMF’s, covering PET and SPECT agents as well as other metabolic imaging agents (small molecules, antibodies and fragments, peptides, recombinant DNA proteins).
From Nowosielski M et al (2014) PLoS ONE. doi:10.1371/journal.pone.0095830
Who We Are
We are expert in scientific, commercial and research analyses related to advanced technologies involving all forms of imaging, isotope supply worldwide and radiation therapy.
From RefleXion Medical Inc, http://www.reflexionmedical.com/#!solution/c209t